Login to Your Account



Clinic Roundup


Friday, May 18, 2012
• Esperance Pharmaceuticals Inc., of Baton Rouge, La., began enrolling patients in a randomized, multicenter Phase II trial of EP-100 plus paclitaxel in advanced ovarian cancer. EP-100 is a targeted membrane-disrupting peptide (tMDP) designed to seek and destroy cancer cells that overexpress luteinizing hormone-releasing hormone receptors on their surfaces.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription